California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.


CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”


U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.


Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.


Health Canada will make an announcement about the regulation of cannabis Tuesday, Nov 21

Ginette Petitpas Taylor, Minister of Health, and Bill Blair, Parliamentary Secretary to the Minister of Justice and Attorney General of Canada and to the Minister of Health, will make an announcement on Tuesday, November 21 about the regulation of cannabis. The announcement will...

Drama in the LP scene: CanniMed acquires Up Cannabis, Aurora gets hostile

On Friday, Nov. 17, CanniMed Therapeutics Inc. (TSX: CMED) announced its acquisition of Newstrike Resources Ltd. (TSX Venture: HIP) in an all-stock agreement while ignoring Aurora Cannabis’ unsolicited acquisition offer, prompting Aurora to launch a formal takeover bid for Ca...

Yukon legalization plan to include public/private retail model

The Yukon intends to have at least one government-run retail store, as well as an online option in time for July 2018 as it works out its plans on how to manage legal cannabis by next year. Long term, the territory intends to have a hybrid public/private retail model with distri...

Quebec Minister says homegrown pot could mean Canadians stoned all day, every day

Quebec’s Minister for Rehabilitation, Youth Protection and Public Health, Lucie Charlebois, says that she thinks allowing homegrown cannabis will mean people will be stoned all day, every day, that kids will eat cannabis plants, and that she has been told there is fentanyl in ...

Tech Talk for Monday November 20th 2017

Pre-opening Comments for Monday November 20th 2017 U.S. equity index futures were mixed this morning. S&P 500 futures were unchanged in pre-opening trade. Wal-Mart dropped $0.89 to $96.58 after Goldman Sachs downgraded the stock to Sector Perform from Outperform. Vale added $0.0...

Canadian legalization round-up

As legalization legislation makes its way through the House of Commons, Canada’s provinces and territories are also working out how to manage and regulate cannabis distribution, sales, age limits, home grows, and more. Bill C-45, the Cannabis Act, is expected to finish debate ...

Product Review: Dipstick Vapes – Dipper Starter Pack

On-the-go globs are the Holy Grail for concentrate connoisseurs: cartridge and atomizer-based “vape pens” provide a sensory experience that’s great if judged on its own merits, but pales in comparison to the unbridled flavor and impact of a proper dab. Even larger portabl...

ACMPR Medical Cannabis Strain Reviews of the Week: November 11-17

The top three reviews of this week, November 4-10, feature top medical cannabis strains from Spectrum, Organigram and THC BioMed. Each of these reviews earned up to 300 Lift Rewards points and will be credited extra points for being featured! Lift Rewards points can be used u...

Product Review: Jane West x Grav – The Beaker

The deep cobalt blue of this bong from the Jane West Collection is a classic glassware color that takes this piece straight into the sophisticated smoking space. Created by Grav Labs, this bong is a sleek scientific companion that’s worthy of the frostiest buds out of your ca...

Chronic Cooking: Waking and Baking Cannabis-infused breakfast muffins and more

Catch Chronic Cooking with Craig Ex and Chef Cody as they whip up a batch of cannabis-infused breakfast favourites. In this first ever episode, you’ll get to find out how to make 3 of Chef Cody’s favourite recipes: The Morning Power Muffin His healthier Whole Wheat Oat Panca...